Understanding the AllTrials Campaign: Its Progress, Impact, and Ongoing Challenges

What Is the AllTrials Campaign and Why Was It Launched?

Launched in 2013, the AllTrials campaign became a defining movement in the fight for full transparency in clinical research. Led by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, AllTrials raised global awareness of the problem of hidden and unreported clinical trial results—particularly those with negative or inconclusive outcomes.

The core slogan, “All Trials Registered. All Results Reported.”, crystallized the campaign’s demands for better transparency, improved access to data, and global policy reform. The concern was not academic—non-publication of trial data leads to evidence gaps in medicine, flawed systematic reviews, biased clinical guidelines, and ultimately, suboptimal patient care.

Founding Members and Their Vision

The campaign’s founding members were influential: Cochrane brought its evidence synthesis legacy; BMJ added editorial authority; and Ben Goldacre, through Bad Pharma, revealed pharmaceutical industry shortcomings. The mission was clear:

• Ensure that all clinical trials are registered in a public database before patient recruitment begins
• Mandate reporting of all trial results, regardless of outcomes
• Encourage retrospective registration and disclosure of past trials
• Push for enforceable legislation across jurisdictions

The campaign filled a void left by slow-moving policy, calling out both public institutions and private sponsors for failing to disclose complete data sets.

Milestones Achieved by the Campaign

The AllTrials campaign has achieved significant global visibility and policy impact over the last decade:

• Over 750 organizations signed the AllTrials petition, including medical societies, research funders, and ethics boards
• EMA’s Policy 0070 and EU Clinical Trial Regulation (EU CTR 536/2014) emerged around the same period, supporting proactive disclosure
• Tools like the FDAAA TrialsTracker were developed to monitor sponsor compliance
• Major journals like The Lancet and BMJ made trial registration a prerequisite for publication

Some companies, such as GSK and Johnson & Johnson, pledged to publish trial results proactively. The UK Health Research Authority (HRA) enforced reporting of all trials approved after 2018.

Public Engagement and Open Data Advocacy

Beyond the policy sphere, AllTrials galvanized public support with a petition that received more than 90,000 signatures globally. This grassroots activism sent a clear message to sponsors and regulators: society demands accountability.

The campaign also aligned itself with broader open data and open science movements, promoting reusable datasets and transparency across disciplines. Many academic institutions were prompted to retrospectively register trials and update their result disclosure practices to avoid reputational harm.

Academic Impact and Journal Response

The campaign influenced academic policy significantly. The International Committee of Medical Journal Editors (ICMJE) reinforced its position on trial registration as a publication condition. Guidelines like CONSORT were updated to emphasize complete and timely results disclosure. Systematic reviews began flagging risk of bias due to missing data more aggressively.

Studies also started evaluating transparency metrics. For instance, a PLOS Medicine analysis in 2020 showed that trial reporting among top-tier research institutions improved post-AllTrials, though gaps remain in smaller, investigator-initiated studies.

Challenges and Barriers to Full Compliance

Despite its success, the campaign faces key barriers:

• Enforcement is weak – Legal penalties for non-compliance remain rare outside the U.S.
• Legacy data is inaccessible – Pre-2007 trials remain largely unpublished, and efforts to retrieve those datasets are underfunded
• Resource gaps at small sponsors – Investigator-led trials often lack administrative support for registration and reporting
• Lack of harmonization – Registries like ClinicalTrials.gov, EU CTR, and ICTRP differ in their formats, making global compliance complex

Efforts to address these gaps continue, with transparency advocates lobbying for tougher laws and better sponsor accountability scorecards. Projects like ClinicalStudies.in are helping train institutions in practical compliance tools and global registry management.

Ongoing Monitoring and Compliance Tools

Transparency monitoring has evolved with technology. Platforms like TranspariMED, EU TrialsTracker, and WHO’s ICTRP now offer dashboards to benchmark disclosure by sponsor, country, and funder. Some regulators have started naming and shaming non-compliant institutions, creating reputational incentives for transparency.

Meanwhile, institutions like PharmaValidation.in are developing SOPs and compliance templates for consistent reporting, reducing administrative burden on research sponsors.

Conclusion: A Campaign That Reshaped Clinical Research Norms

The AllTrials campaign permanently changed how clinical research is conducted, reviewed, and disseminated. From patient advocacy to policy reform and journal mandates, the campaign has made a lasting mark.

However, transparency is a continuous journey. The next decade will require stricter enforcement, smarter registries, and full data accessibility—especially in underrepresented regions. The AllTrials legacy remains a blueprint for future movements fighting for ethical, evidence-based science in public health.

To explore global guidelines aligned with AllTrials values, visit the ICH Quality Guidelines and related transparency publications from PharmaRegulatory.in.

How to Correct and Update ClinicalTrials.gov Trial Records Effectively

Why Updates and Corrections Are Crucial

ClinicalTrials.gov serves as the public-facing record of clinical studies and their outcomes. Maintaining an accurate, up-to-date registry is not just good practice—it is a regulatory requirement under FDAAA 801, 42 CFR Part 11, and ICMJE policies. Sponsors and investigators must ensure that their study records reflect protocol changes, recruitment status, and result postings accurately. Failure to update trial data may lead to compliance issues, public mistrust, and publication rejections. This article walks you through the processes, responsibilities, timelines, and best practices for correcting and updating trial records.

What Fields Require Updating?

There are several critical data points in a ClinicalTrials.gov record that require periodic or event-driven updates. These include:

• Recruitment Status: Must be updated within 30 days of a change (e.g., from “Recruiting” to “Completed”)
• Study Start Date: If delayed, should reflect the actual date of first subject enrollment
• Primary Completion Date: Must be revised when final primary data collection concludes
• Outcome Measures: Should align with protocol amendments
• PI Contact Details: Must be kept current for public queries
• Results Submission: Due within 12 months of primary completion date (for applicable trials)

Updates must be made through the PRS (Protocol Registration and Results System), using the appropriate login credentials and edit rights.

Accessing the Record: User Roles in PRS

Access to the trial record in ClinicalTrials.gov is governed by the PRS user hierarchy. A study team may include the following roles:

• Administrator: Controls user permissions and is responsible for overall record management
• Record Owner: Typically creates and maintains the trial record
• Standard User: May edit assigned sections but cannot release final records

If you need to correct data and don’t have edit rights, contact your institutional PRS administrator. For sponsor-managed studies, ensure a formal delegation trail exists. See sponsor SOP templates at PharmaSOP.in.

Step-by-Step: Making an Update in PRS

To correct or update a trial record, follow this process:

1. Log in to PRS using your assigned credentials
2. Click on the “Records” tab and select your study by NCT number
3. Select “Edit” and navigate to the field needing correction
4. Make the necessary changes and provide comments in the “Review History” section (if available)
5. Run “Protocol Validation” to check for entry errors
6. Click “Entry Complete” when done, and then “Release” to send for review

The PRS system will generate an audit trail, timestamping all modifications. You must ensure consistency with the approved protocol and other registries (e.g., EU-CTR if applicable).

Dealing with Protocol Amendments

Protocol changes that affect registry data—such as adding new outcome measures or changing sample size—must be reflected in the ClinicalTrials.gov record. A common issue is delay in registry update following IRB approval. Ideally, registry updates should occur within 30 days of the amendment approval date. Document the change using a structured log like the example below:

Keep this log in the Trial Master File (TMF) and append it to any sponsor audit trail system. Review guidelines from FDA and ICH E6(R2) for reference.

Correcting Errors Post-Submission

If your registry entry has already been released and is live on ClinicalTrials.gov, and you identify an error (e.g., incorrect study start date, wrong phase, missing arms), don’t panic. The PRS allows corrections post-release. Simply:

• Open the record and make the correction under “Edit” mode
• Add a reviewer note clarifying the change (e.g., “Corrected phase from Phase 1 to Phase 2 as per protocol v3.0”)
• Run validation and resubmit

Note that for major corrections, ClinicalTrials.gov may flag the record or return it for clarification. The change history is publicly visible, so transparency is key.

Results Corrections and Resubmissions

Once results are submitted and published, you may still need to correct errors or clarify outputs. Common corrections include:

• Statistical method errors
• Incorrect units (e.g., mg vs μg)
• Misreported confidence intervals or p-values

Resubmit using the “Results” section in PRS. Provide a note in the “Reviewer Comments” section to document the reason for change. All previous versions remain visible to ensure full transparency and GCP compliance.

Tips for Maintaining an Audit-Ready Record

Regulatory authorities and ethics committees may request a record of all registry updates. Here’s how to stay audit-ready:

• Maintain an internal update log for each record
• Document who made the change, when, and why
• Cross-check registry data against protocol, ICF, and IRB approvals
• Set calendar reminders for routine 6-month registry reviews
• Train team members in PRS usage and registry compliance

Use built-in tracking features or maintain a registry change control SOP. Templates are available on PharmaValidation.in.

Case Study: Missed Primary Completion Date Update

Background: A biotech company completed patient visits in March but failed to update the Primary Completion Date until July. This delayed results submission and attracted NIH warning notices.

Resolution: They retroactively documented the actual completion date, notified ClinicalTrials.gov of the oversight, and submitted results within 30 days thereafter.

Lesson: Establish ownership and regular monitoring to prevent such oversights. Automate reminders via Excel, Outlook, or CTMS integration.

Conclusion

Correcting and updating trial records on ClinicalTrials.gov is not just a clerical task—it’s a regulatory and ethical obligation. Timely updates, transparent corrections, and careful tracking of changes protect trial integrity, support scientific transparency, and ensure audit readiness. Make registry maintenance a team responsibility, backed by SOPs, training, and digital tools. Whether you’re a sponsor, CRO, or investigator, managing trial records diligently reflects your commitment to research accountability.

For more guidance, visit PharmaGMP.in or refer to global best practices on WHO Publications.